Related by context. All words. (Click for frequent words.) 69 hematologic toxicity 68 toxicity 67 nephrotoxicity 66 dose limiting toxicities 66 myelosuppression 66 hypersensitivity reactions 66 neurotoxicity 66 Toxicities 65 cardiac toxicity 64 febrile neutropenia 64 hematological toxicity 64 renal toxicity 63 gastrointestinal toxicities 63 Adverse events 63 mucositis 63 neutropenia 63 hematologic adverse 63 infusion reactions 63 bone marrow suppression 63 limiting toxicity 62 corticosteroid therapy 62 laboratory abnormalities 62 hepatotoxicity 62 myopathy rhabdomyolysis 62 antitumor activity 61 systemic toxicity 61 thromboembolic events 61 hyperbilirubinemia 61 thrombocytopenia 61 DLTs 61 mycophenolate mofetil 61 hematological toxicities 60 cardiotoxicity 60 QTc prolongation 60 cytotoxic chemotherapy 60 discontinuations 60 hematologic toxicities 60 systemic absorption 60 leucopenia 60 malignancies 59 alpha interferons 59 mitochondrial toxicity 59 overlapping toxicities 59 non hematological toxicities 59 AEs 59 hyperkalemia 59 hepatic toxicity 59 posaconazole 59 peripheral sensory neuropathy 58 severe hypersensitivity reactions 58 hypercalcemia 58 immunosuppressive agents 58 cytotoxicity 58 pheochromocytoma 58 QT prolongation 58 sunitinib 58 gastrointestinal toxicity 58 EGFRIs 58 chemotherapeutic agents 58 neutropaenia 58 thrombocytopenia neutropenia 58 glucose lowering 58 pharmacokinetic interactions 58 hematological adverse 58 vandetanib 58 transaminase elevations 57 lenalidomide dexamethasone 57 leukopenia 57 dasatinib 57 mTOR inhibitors 57 teriflunomide 57 antitumor effect 57 etoposide 57 lymphopenia 57 imatinib 57 thrombotic events 57 proteasome inhibitors 57 FOLPI 57 carcinomas 57 immunomodulators 57 Febrile neutropenia 57 intravenous bisphosphonates 57 PREZISTA r 57 ALT flares 57 elotuzumab 57 haematologic 57 tolvaptan 57 aprepitant 57 Tindamax R 57 HMG CoA reductase inhibitors 57 hypoglycemic events 57 Cisplatin 57 nephrotoxic 57 microvascular complications 56 liver toxicity 56 neutropenia thrombocytopenia 56 EXJADE 56 hematologic 56 chemoradiation 56 chemotherapies 56 temsirolimus 56 chemotherapy regimens 56 hypersensitivity reaction 56 immunological responses 56 tolerability 56 adverse reactions 56 bortezomib 56 platinum refractory 56 venous thromboembolic events 56 chlorambucil 56 adrenal suppression 56 virological failure 56 pertuzumab 56 anti leukemic 56 events AEs 56 cisplatin 56 tumor recurrence 56 APTIVUS r 56 idarubicin 56 neutropenia febrile neutropenia 56 androgen deprivation 56 sarcomas 56 Hypersensitivity reactions 56 antiviral activity 56 lupus nephritis 56 treatment emergent adverse 56 Hematologic toxicity 56 erythropoietic 56 imetelstat 56 gemcitabine 55 non selective NSAIDs 55 interferon IFN 55 mg/m2 dose 55 cutaneous squamous cell carcinoma 55 hemorrhagic complications 55 topotecan 55 receiving VICTRELIS 55 mg kg dose 55 calcineurin inhibitors 55 immunosuppression 55 amphotericin B 55 virologic response 55 heavily pretreated 55 androgen suppression 55 EGFR inhibitors 55 pegylated liposomal doxorubicin 55 sirolimus 55 alkylating agent 55 events SAEs 55 non metastatic osteosarcoma 55 Neutropenia 55 interferon alfa 55 chemoradiotherapy 55 azacitidine 55 lipid lowering therapies 55 trimethoprim sulfamethoxazole 55 TEAEs 55 tolerability profile 55 acute GvHD 55 ZYVOX 55 leucovorin 55 KRAS status 55 cilengitide 55 infliximab Remicade 55 macrovascular events 55 taxanes 55 deferiprone 55 superficial bladder cancer 55 antidiabetic drugs 55 TMP SMX 55 mitoxantrone 55 cisplatin chemotherapy 55 rituximab 55 ALT elevations 55 imatinib therapy 55 hydroxychloroquine 55 dermatologic toxicities 55 sorafenib Nexavar 55 lactic acidosis 55 delayed CINV 55 myelosuppressive 55 bevacizumab Avastin 55 DMARDS 55 NNRTI resistance 55 FOLFOX 55 octreotide LAR 55 cetuximab 55 fluorouracil 55 VEGF inhibitors 55 visilizumab 55 virologic failure 55 bezafibrate 55 CYP #A# 55 octreotide 55 FOLFIRI 55 COPD exacerbations 55 rFVIIa 55 advanced adenomas 55 Dasatinib 55 GVHD 55 discontinuations due 55 celecoxib 55 hypophosphatemia 55 insulin sensitizers 55 docetaxel Taxotere 55 adjuvant therapy 55 severe hypoglycemia 55 CTAP# Capsules 55 cranial irradiation 55 intracranial hemorrhage ICH 55 DMARDs 55 Elitek 55 FluCAM arm 55 lymphomas 55 hypoglycemic episodes 55 sulfasalazine 54 hematologic abnormalities 54 NNRTIs 54 autoimmune reactions 54 dosing frequency 54 neutropenia dehydration dyspnea 54 ocular adverse 54 OADs 54 cisplatin carboplatin 54 cytopenias 54 hepatic adverse 54 ceftriaxone 54 GEMZAR 54 primidone 54 standard chemotherapy regimens 54 CMV infection 54 PDE4 inhibitors 54 docetaxel chemotherapy 54 sotalol 54 VAPRISOL 54 refractory gout 54 grade glioma 54 cidofovir 54 chemotherapeutic regimens 54 fondaparinux 54 mapatumumab 54 anaphylactic reactions 54 anticancer treatments 54 hypomagnesemia 54 monotherapy 54 zoledronic acid 54 statin medications 54 antiarrhythmic drugs 54 Dapagliflozin 54 platelet reactivity 54 gemifloxacin 54 cisplatin gemcitabine 54 antiangiogenic agents 54 Flu Cy 54 antiemetics 54 carboplatin paclitaxel 54 heavily pretreated patients 54 acute leukemias 54 hepatic dysfunction 54 vinorelbine 54 clinically meaningful differences 54 metastatic disease 54 bexarotene 54 comparator arm 54 anti coagulant therapy 54 LHRH analogues 54 inhaled nitric oxide 54 chemotherapeutic drugs 54 β blockers 54 neutropenic 54 Peg IFN 54 angioedema 54 TORISEL 54 durable remissions 54 telithromycin 54 extrapyramidal symptoms 54 systemically administered 54 tigecycline 54 antitumor efficacy 54 metastatic RCC 54 microtubule targeting 54 acute gout flares 54 ERBITUX 54 pyridostigmine 54 ribavirin therapy 54 Combination therapy 54 intravesical 54 tocilizumab 54 bone metastases 54 daunorubicin 54 DOXIL 54 pomalidomide 54 caspofungin 54 metastases 54 tolerability profiles 54 disease progression 54 hydroxyurea 54 SAEs 54 pamidronate 54 locoregional recurrence 54 dose regimens 54 virologic responses 54 docetaxel Taxotere ® 54 neuroblastomas 54 cytotoxic effects 54 endometrial hyperplasia 54 pulmonary toxicity 54 Pegylated Interferon 54 dapsone 54 ISTODAX 54 hormonal therapies 54 5-FU/LV 54 dosage regimens 54 myeloablative 54 iniparib 54 androgen ablation 53 CIMZIA ™ 53 elevated ALT 53 osteosarcomas 53 lymphadenopathy 53 fluvastatin 53 NRTI 53 immunosuppressive 53 solifenacin 53 antitumor effects 53 tipranavir 53 tumor regression 53 FOSRENOL ® 53 danazol 53 acute toxicity 53 trans retinoic acid 53 hypotension 53 pimecrolimus 53 glycemia 53 lymphoma subtypes 53 dosing schedules 53 antiepileptics 53 bovine thrombin 53 Cremophor 53 raltegravir 53 brain metastases 53 conventional DMARDs 53 pharmacodynamic 53 nocturnal hypoglycaemia 53 beta agonists 53 antiviral efficacy 53 5FU 53 idraparinux 53 endophthalmitis 53 QT interval prolongation 53 tumor lysis syndrome 53 relapsed ovarian cancer 53 pancytopenia 53 potentially hepatotoxic 53 indomethacin 53 BARACLUDE 53 adalimumab 53 dacarbazine 53 neuroendocrine tumors 53 FOLFOX4 53 DFMO 53 Bezielle 53 myeloproliferative diseases 53 sorafenib 53 severe neutropenia 53 chemopreventive agents 53 deferoxamine 53 cyclophosphamide 53 CIMZIA TM 53 surrogate endpoint 53 neutrophil counts 53 mRCC 53 pegfilgrastim 53 Erlotinib 53 invasive candidiasis 53 antiplatelet drugs 53 pCR 53 resistant ovarian cancer 53 angiotensin converting enzyme inhibitors 53 biochemical abnormalities 53 eculizumab 53 esophagitis 53 renal insufficiency 53 anthracycline chemotherapy 53 dosing regimens 53 antihypertensive medications 53 somatostatin analogs 53 Fludara 53 hypocalcemia 53 EGFR antibodies 53 chemotherapeutics 53 interferon ribavirin 53 anakinra 53 thalidomide Thalomid 53 IV bisphosphonates 53 dose cytarabine 53 HBeAg positive patients 53 prednisone prednisolone 53 Hepatotoxicity 53 pegylated interferons 53 milatuzumab 53 griseofulvin 53 genotypic resistance 53 grade gliomas 53 tardive dyskinesia TD 53 bleomycin 53 antiangiogenic therapy 53 GnRH agonists 53 coadministration 53 Thrombocytopenia 53 abatacept 53 thromboembolic 53 rizatriptan 53 pemetrexed 53 CA4P 53 asthma exacerbations 53 piperacillin tazobactam 53 platelet inhibitor 53 histologies 53 gemcitabine Gemzar 53 neoplasms 53 TNF antagonist 53 anthracyclines 53 zalutumumab 53 xenograft models 53 nelfinavir 53 TELINTRA 53 metastatic lung cancer 53 nab paclitaxel 53 antitumor 53 cabazitaxel 53 anemia neutropenia 53 ibandronate 53 Navelbine 53 JAK inhibitors 53 PegIFN RBV 53 DMARD 53 ansamycin 53 Azedra 53 chemopreventive 53 fulvestrant 53 ACTEMRA 53 docetaxel 53 oral allopurinol 53 atopic disease 53 chemotherapeutic 53 PEGylated interferon beta 1a 53 plasma uric acid 53 plus 5-FU/LV 53 exacerbations 53 allopurinol 53 clodronate 53 abacavir lamivudine 53 itraconazole 53 Myelosuppression 53 Irinotecan 53 reactogenicity 53 leukotriene receptor antagonists 53 treatment regimens 53 antiandrogen 53 tumor regressions 53 NRTIs 52 proteinuria 52 pegylated interferon alfa 2b 52 virologic breakthrough 52 nucleoside analogues 52 potassium sparing diuretics 52 glucocorticoids 52 MGUS 52 doxorubicin docetaxel 52 therapeutic regimens 52 riociguat 52 receptor inhibitor 52 LEP ETU 52 paclitaxel Taxol 52 gefitinib 52 Serious adverse reactions 52 deferasirox 52 6R BH4 52 sulphonylureas 52 BEACOPP 52 hypoglycaemia 52 H. pylori eradication 52 limiting toxicity DLT 52 tumor shrinkage 52 neutropenic patients 52 IRX 2 52 sitagliptin 52 treatment emergent AEs 52 Fludarabine 52 bacteriuria 52 aflibercept 52 basal cell carcinoma BCC 52 decitabine 52 Candida infection 52 anti angiogenic drugs 52 CMV disease 52 insulin detemir 52 ritonavir boosted 52 complete remissions 52 HGS# 52 postoperative chemotherapy 52 demonstrated antitumor activity 52 metastatic neuroendocrine tumors 52 protamine 52 nonmelanoma skin cancers 52 topical corticosteroids 52 lipid parameters 52 invasive aspergillosis 52 IFN alpha 52 bevacizumab 52 adverse effects 52 ACTEMRA TM 52 chemotherapy induced neutropenia 52 colorectal liver metastases 52 Doxorubicin 52 glycated hemoglobin levels 52 coagulopathy 52 relapsed SCLC 52 Doxil ® 52 azacytidine 52 adalimumab Humira 52 S/GSK# 52 oral diclofenac 52 strong CYP#A# inhibitors 52 haematological toxicity 52 Neulasta ® 52 candidemia 52 teratogenic 52 chronic GVHD 52 uncontrolled seizures 52 panobinostat 52 thrombotic complications 52 skeletal metastases 52 lipid abnormalities 52 erlotinib 52 docetaxel Taxotere R 52 mycophenolate mofetil MMF 52 BARACLUDE ® 52 ciclosporin 52 fluorouracil leucovorin 52 OHR/AVR# 52 alpha 2a 52 Oral corticosteroids 52 adrenal insufficiency 52 Vidaza ® 52 EBRT 52 PEG Interferon lambda 52 bevacizumab Avastin ® 52 immunosuppressive regimens 52 HGS ETR1 52 lamotrigine 52 metastatic malignant melanoma 52 efficacy 52 Anthracycline 52 immunomodulatory therapy 52 dose escalation 52 motesanib 52 antithrombotic therapy 52 hypokalemia 52 carcinoid tumors 52 antiepileptic drug 52 pyrazinamide 52 distant metastasis 52 Adalimumab 52 INTELENCE 52 chemoresistance 52 ketoconazole 52 interstitial pneumonia 52 leflunomide 52 nephrotoxic drugs 52 MGd 52 metastatic cancers 52 valacyclovir 52 glucocorticoid 52 cytogenetic response 52 intermittent dosing 52 plasma concentrations 52 myelodysplastic syndromes MDS 52 trastuzumab 52 gastric irritation 52 quinolones 52 HbA1c levels 52 dosed orally 52 fosamprenavir 52 Gliomas 52 ototoxicity 52 cytotoxic 52 dose colchicine 52 fluconazole 52 nonrandomized 52 Cytoxan 52 tyrosine kinase inhibitors 52 Vidofludimus 52 hypoglycemia 52 immunosuppressive regimen 52 ara C 52 reperfusion injury 52 lopinavir r 52 locoregional 52 Hematologic 52 beta lactam antibiotic 52 dasatinib Sprycel ® 52 uric acid lowering 52 TKI therapy 52 quinoline 52 achieved statistical significance 52 SCCHN 52 chemotherapy docetaxel 52 voriconazole 52 retinoid 52 reflux symptoms 52 Torsades de Pointes 52 hypercholesterolemia 52 tanespimycin 52 atypical antipsychotic medications 52 VIDAZA 52 oral antidiabetes 52 concomitant medications 52 denileukin diftitox 52 infliximab 52 amiodarone 52 secondary efficacy endpoints 52 mitomycin 52 K ras mutations 52 TNF inhibitor 52 oral NSAIDs 52 neurologic complications 52 incidence ≥ 52 HER2 overexpression 52 relapsing multiple sclerosis 52 follicular lymphoma FL 52 allograft rejection 52 peg IFN 52 strong CYP#A# inducers 52 selenium supplementation 52 recurrent venous thromboembolism 52 dacetuzumab 52 symptomatic VTE 52 azathioprine 52 acarbose 52 corticosteroid dexamethasone 52 dexamethasone Decadron 52 DAPT 52 MMP inhibitors 52 gastrointestinal perforation 52 REMICADE ® 52 related hematological toxicity 52 corticosteroids 52 colorectal tumors 52 PREZISTA rtv 52 solar keratoses 52 micafungin 52 CYT# potent vascular disrupting 52 cytarabine daunorubicin 52 pharmacodynamics PD 52 LHRH agonists 52 Taxol paclitaxel 52 pneumonectomy 52 hepatotoxic 52 NATRECOR ® 52 OAB symptoms 52 parkinsonian symptoms 51 talabostat 51 vesicoureteral reflux 51 pharmacologic 51 cytoreductive surgery 51 sequelae 51 infusional 51 hypoglycaemic episodes 51 adefovir 51 imatinib resistance 51 TNF alpha antagonists 51 HbA 1c levels 51 postoperative mortality 51 external genital lesions 51 adjuvant radiotherapy 51 anticancer therapies 51 Candida infections 51 grade cervical intraepithelial 51 GvHD 51 cancers 51 EDARBI 51 ganciclovir 51 preclinically 51 lymphocyte counts 51 amoxicillin clavulanate 51 nitrofurantoin 51 anticancer therapy 51 nicardipine 51 IGFBP 3 51 neutropenia anemia 51 postoperative morbidity 51 amifostine 51 gastrointestinal bleeds 51 darunavir r 51 HBeAg positive 51 MEK inhibitors 51 RSV infection 51 EGFr 51 epithelial tumors 51 elevated plasma concentrations 51 dopaminergic therapy 51 AST ALT 51 LHRH antagonists 51 fibrotic disease 51 aldosterone antagonist 51 glitazones 51 cytotoxic agents 51 immune suppressants 51 Vandetanib 51 alkylating agents 51 HBeAg negative 51 sensory neuropathy 51 KETEK 51 premedication 51 tumor xenograft models 51 severe rotavirus gastroenteritis 51 ximelagatran 51 Glucocorticoids 51 peripheral neuropathy CIPN 51 perioperative complications 51 intensive statin therapy 51 linear pharmacokinetics 51 acitretin 51 hypertensive patients 51 adecatumumab 51 invasive fungal infections 51 methotrexate 51 standard chemotherapy regimen 51 hemodilution 51 oblimersen 51 bendamustine 51 Vidaza azacitidine 51 interferon alfa 2b 51 cardiotoxic 51 serum calcium 51 monoamine oxidase inhibitors 51 AEGR 51 nanomolar 51 Mitoxantrone 51 N acetylcysteine 51 Symadex 51 antibiotic regimens 51 retapamulin 51 cediranib 51 histologic subtype 51 hyperprolactinemia 51 valproic acid 51 contrast induced nephropathy 51 bortezomib Velcade 51 paclitaxel cisplatin 51 noscapine 51 uridine triacetate 51 serum phosphate levels 51 μg dose 51 exocrine pancreas 51 cerebrovascular events 51 microglial activation 51 forodesine 51 LMWH 51 cSSSI 51 comorbid conditions 51 Myelofibrosis 51 autoantibody levels 51 Elevated liver enzymes 51 prognostic factors 51 patients receiving ERBITUX 51 flutamide 51 macrovascular complications 51 mixed hyperlipidemia 51 liver metastases 51 fallopian tube carcinoma 51 dexpramipexole 51 urate lowering 51 CCyR 51 canakinumab 51 azole 51 baseline HbA1c 51 bone metastasis 51 immunosuppressive therapies 51 anti TNF 51 acute tubular necrosis 51 external beam radiotherapy 51 Darinaparsin 51 vasomotor symptoms 51 solid tumors 51 axitinib 51 anticancer activity 51 gastrointestinal adverse reactions 51 TNF α 51 biologic DMARD 51 cerebral vasospasm 51 atacicept 51 Adjuvant chemotherapy 51 urothelial carcinoma 51 beclomethasone dipropionate 51 basal cell carcinomas 51 mg BID 51 CMV reactivation 51 hemorrhagic cystitis 51 hepatic failure 51 hemoptysis 51 HBV replication 51 fluid overload 51 leukemia AML 51 Taxotere R 51 prolactin levels 51 TELCYTA 51 ocular toxicity 51 pyrexia mucositis sepsis febrile 51 4mg/kg 51 pericardial effusion 51 erlotinib Tarceva ® 51 cardioprotective effects 51 antitumour 51 adjuvant therapies 51 carboplatin 51 platelet inhibition 51 doxorubicin cyclophosphamide 51 fatigue asthenia 51 scalp psoriasis 51 eosinophilia 51 LEXIVA r 51 Nilotinib 51 abciximab 51 aminotransferases 51 AChE inhibitors 51 pharmacokinetic characteristics 51 chemopreventive agent 51 GISTs 51 bladder cancers 51 gout flares 51 kinase inhibition 51 epirubicin 51 thromboembolism 51 acromegalic patients 51 relapsed MM 51 prucalopride 51 cytoreduction 51 chemotherapeutic drug 51 reinfarction 51 obatoclax 51 thrombocytosis 51 insulin glargine 51 insulin degludec 51 biphosphonates 51 postmarketing surveillance 51 nonvertebral fractures 51 topical calcineurin inhibitors 51 gemcitabine cisplatin 51 anemias 51 biodistribution 51 dose cyclophosphamide 51 thiopurine 51 INCB# [003] 51 neoadjuvant 51 RAPAFLO R 51 O PPDS 51 ORENCIA 51 teriparatide 51 PRT# 51 liver transaminases 51 CANCIDAS 51 generalized seizures 51 distant metastases 51 Discontinuations 51 amrubicin 51 renal dysfunction 51 selective NSAIDs 51 metaglidasen 51 lichen planus 51 factor Xa inhibitor 51 EGFR tyrosine kinase inhibitors 51 sorafenib Nexavar ® 51 cardiovascular morbidity 51 insulin sensitizing 51 montelukast 51 TZDs 51 antiarrhythmic 51 atypical fractures 51 administered subcutaneously 51 JANUVIA 51 cholecystitis 51 sustained virologic response 51 tumor necrosis 51 mucosal inflammation 51 tumor histology 51 serum creatinine levels 51 hyperglycemia 51 hyperoxaluria 51 recurrences 51 Stent thrombosis 51 TTF Therapy 51 certolizumab 51 chronic urticaria 51 miconazole 51 adriamycin 51 proton pump inhibitor PPI 51 DMARD therapy 51 timepoints 51 pathologic fractures 51 sulfonylurea 51 hypercholesterolaemia 51 SCH # 51 acute coronary syndromes ACS 51 colchicine 51 granisetron 51 serum concentrations 51 dexrazoxane 51 anastrozole 51 TNF inhibitors 51 CR nPR 51 pimozide 51 NOMID 51 ancrod 51 neoplasias 51 peptide antigens 51 immunomodulation 51 efavirenz Sustiva 51 HuLuc# 51 HAART regimens 51 vincristine 51 investigational monoclonal antibody 51 BRAF inhibitor 51 confounding variables 51 transgene expression 51 Paraplatin ® 51 hyperphenylalaninemia HPA due 51 diarrhea nausea fatigue 51 refractory NSCLC 51 CIPN 51 Traficet EN 51 GFT# 50 Revlimid lenalidomide 50 TYSABRI treated 50 glitazone class 50 thromboprophylaxis 50 Vicinium TM 50 mercaptopurine 50 severe oral mucositis 50 ALIMTA 50 MYCAMINE 50 immune suppression 50 gemcitabine Gemzar ® 50 GIST tumors 50 vicriviroc 50 cervical intraepithelial neoplasia 50 combinability 50 GRN#L 50 chemotherapy gemcitabine 50 TG# [003] 50 Panzem R NCD 50 telcagepant 50 nerve toxicity neurotoxicity 50 Targretin 50 anti angiogenic agents 50 oral antidiabetes drugs 50 recurrent UTI 50 Navelbine ® 50 capillary leak 50 torsade de pointes 50 paroxetine Paxil 50 MAO inhibitors 50 interferon 50 bolus dose 50 anaphylactoid reactions 50 TACE 50 induce apoptosis 50 ALA PDT 50 HBeAg seroconversion 50 Dose adjustments 50 homozygous familial hypercholesterolemia 50 Cytarabine 50 cyclosporine 50 Bortezomib 50 Peripheral edema 50 bosentan 50 Zoledronic acid 50 inecalcitol 50 myelofibrosis 50 CHOP chemotherapy 50 elevated creatinine 50 rebleeding 50 salmeterol fluticasone 50 antiviral therapy 50 colorectal adenoma 50 metastatic renal cell carcinoma 50 anti mitotic 50 RISPERDAL ® 50 xanthine oxidase inhibitor 50 evaluating tivozanib 50 gemcitabine carboplatin 50 Hypotension 50 valopicitabine 50 lapatinib Tykerb 50 anticoagulation 50 hyperphosphatemia 50 intravenous dosing